Saturday, 31 October 2026European Markets

VEON Stock Soars 18% As Trading Day Concludes!

Loading stream...

(VIANEWS) - VEON shares surge 18.51% on the AEX-Index Shares of VEON (AEX-Index: VEON.AS) experienced an extraordinary surge of 18.51% to EUR0.73 at 15:08 EST on Wednesday, continuing its upward trajectory from previous sessions. Despite being part of an AEX-Index that declined 0.57% overall (EUR732.50), this marked a distinct reversal in trend after five consecutive losses over previous five sessions; though overall this day exhibited negative signs.

About VEON

VEON Ltd is a telecom company founded in 1992 that offers mobile and fixed-line voice, data, wireless internet services to corporates, operators, consumers and mobile finance customers in Russia, Pakistan, Algeria, Uzbekistan Ukraine Bangladesh Kazakhstan Kyrgyzstan Georgia under various brands. Headquartered in Amsterdam the Netherlands.

Technical Analysis

VEON, the global telecom company, experienced an astonishing surge in trading volume today - 10.259.90 shares changed hands compared to its 50-day average volume of 98.830. This may indicate increased investor interest and potentially move the stock in either direction. Volatility analysis shows VEON as experiencing a negative 0.20% intraday variance over the last week, negative 0.21% over one month, and positive 2.19% variation over three months - indicative of some uncertainty surrounding this stock in recent times. According to the stochastic oscillator, an influential technical indicator designed to monitor overbought and oversold conditions, VEON stock currently appears oversold with a reading below 20 on its stochastic oscillator indicator, suggesting it may be undervalued and likely in for an upward price surge in due time. Overall, investors in VEON should keep a close eye on its price movements as well as any news or developments that could have an effect on its price. Investors may wish to consider any impact from COVID-19 pandemic on telecom industry performance as well as regulatory changes or market shifts which might alter performance of VEON shares.

Equity Analysis

Based on its financial data, VEON has an estimated trailing twelve months EPS of EUR0.26. This indicates that they earned this amount per share during the past twelve months - providing investors with vital insight into VEON's profitability. Additionally, the company boasts a trailing twelve months PE ratio of 2.81, which indicates that investors are willing to pay EUR2.81 per euro of annual earnings for every share in circulation. This ratio helps investors assess whether their stock may be over or undervalued; higher PE ratios indicate potential overvaluation while lower PE ratios could indicate possible undervaluation. Overall, VEON's earnings per share and PE ratio suggest it is profitable; however, investors should carefully assess current market conditions and other considerations before making investment decisions.

More news about VEON (VEON.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com